Status:

COMPLETED

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

Lead Sponsor:

BrightGene Bio-Medical Technology Co., Ltd.

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of BGM0504 in Chinese patients with Type 2 Diabetes.

Eligibility Criteria

Inclusion

  • Have been diagnosed with type 2 diabetes mellitus (T2DM);
  • Glycosylated hemoglobin (HbA1c) at screening/baseline: 7.0% ≤ HbA1c ≤ 10%;
  • Body Mass Index (BMI): 19.5 kg/m2 ≤ BMI ≤ 35.0 kg/m2;
  • Fasting blood glucose (FPG) at screening/baseline: FPG ≤ 13.3 mmoL/L

Exclusion

  • Diagnosed with non-type 2 diabetes mellitus;
  • Grade 3 hypoglycemia within 6 months prior to screening;
  • Concomitant thyroid dysfunction that cannot be controlled at a stable drug dose at screening, or clinically significant abnormalities in thyroid function test results at screening that require initiation of therapy;
  • Subjects with uncontrolled hypertension after treatment (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening) or untreated blood pressure meeting the above criteria at screening;
  • Patients with a previous history or clinical evidence of acute or chronic pancreatitis;
  • Malignant tumor confirmed within 5 years prior to screening (except cured carcinoma in situ) or potential malignant tumor assessed at screening;
  • Patients with severe mental illness or language disorder at screening, unwilling or unable to fully understand and cooperate;
  • Female subjects during pregnancy or lactation.

Key Trial Info

Start Date :

August 30 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 13 2024

Estimated Enrollment :

67 Patients enrolled

Trial Details

Trial ID

NCT06974825

Start Date

August 30 2023

End Date

August 13 2024

Last Update

May 16 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes | DecenTrialz